Literature DB >> 27938999

Overcoming radioresistance in head and neck squamous cell carcinoma.

Vicky N Yamamoto1, David S Thylur2, Michael Bauschard2, Isaac Schmale3, Uttam K Sinha2.   

Abstract

Radiation therapy plays an essential role in the treatment of head and neck squamous cell carcinoma (HNSCC), yet therapeutic efficacy is hindered by treatment-associated toxicity and tumor recurrence. In comparison to other cancers, innovation has proved challenging, with the epidermal growth factor receptor (EGFR) antibody cetuximab being the only new radiosensitizing agent approved by the FDA in over half a century. This review examines the physiological mechanisms that contribute to radioresistance in HNSCC as well as preclinical and clinical data regarding novel radiosensitizing agents, with an emphasis on those with highest translational promise.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DNA damage; Head and neck cancer; Head and neck squamous cell carcinoma; Molecular targeted therapy; Radiation resistance; Radiation-sensitizing agents; Radioresistance; Radiotherapy

Mesh：

Substances：

Year:  2016        PMID： 27938999     DOI： 10.1016/j.oraloncology.2016.11.002

Source DB:  PubMed          Journal:  Oral Oncol        ISSN： 1368-8375            Impact factor:   5.337


  13 in total

1.  LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.

Authors:  Linlin Yang; Bhavna Kumar; Changxian Shen; Songzhu Zhao; Dukagjin Blakaj; Tianyun Li; Mitchell Romito; Theodoros N Teknos; Terence M Williams
Journal:  Mol Cancer Ther       Date:  2019-04-23       Impact factor: 6.261

2.  Radiation modulates expression and related activities of c-Met protein in oral tongue squamous cell carcinoma cell lines.

Authors:  Aisha A H Al-Jamaei; Jan G A M de Visscher; Tymour Forouzanfar; Ruud H Brakenhoff; C René Leemans; Arwen Stikvoort; Behrouz Zandieh-Doulabi; Marco N Helder
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-02       Impact factor: 4.322

3.  Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment.

Authors:  Ayman J Oweida; Shilpa Bhatia; Benjamin Van Court; Laurel Darragh; Natalie Serkova; Sana D Karam
Journal:  J Vis Exp       Date:  2019-04-22       Impact factor: 1.355

4.  Oncoprotein Tudor-SN is a key determinant providing survival advantage under DNA damaging stress.

Authors:  Xiao Fu; Chunyan Zhang; Hao Meng; Kai Zhang; Lei Shi; Cheng Cao; Ye Wang; Chao Su; Lingbiao Xin; Yuanyuan Ren; Wei Zhang; Xiaoming Sun; Lin Ge; Olli Silvennoinen; Zhi Yao; Xi Yang; Jie Yang
Journal:  Cell Death Differ       Date:  2018-02-19       Impact factor: 15.828

5.  Association Between Head and Neck Squamous Cell Carcinoma Survival, Smoking at Diagnosis, and Marital Status.

Authors:  Nosayaba Osazuwa-Peters; Eric Adjei Boakye; Betty Y Chen; Betelihem B Tobo; Mark A Varvares
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-01-01       Impact factor: 6.223

6.  PEGylated liposome-encapsulated rhenium-188 radiopharmaceutical inhibits proliferation and epithelial-mesenchymal transition of human head and neck cancer cells in vivo with repeated therapy.

Authors:  Chun-Yuan Chang; Chao-Cheng Chen; Liang-Ting Lin; Chih-Hsien Chang; Liang-Cheng Chen; Hsin-Ell Wang; Te-Wei Lee; Yi-Jang Lee
Journal:  Cell Death Discov       Date:  2018-10-31

7.  A patient tumour-on-a-chip system for personalised investigation of radiotherapy based treatment regimens.

Authors:  R Kennedy; D Kuvshinov; A Sdrolia; E Kuvshinova; K Hilton; S Crank; A W Beavis; V Green; J Greenman
Journal:  Sci Rep       Date:  2019-04-19       Impact factor: 4.379

8.  Macrophage migration inhibitory factor modulates proliferation, cell cycle, and apoptotic activity in head and neck cancer cell lines.

Authors:  Kusumawadee Utispan; Sittichai Koontongkaew
Journal:  J Dent Sci       Date:  2020-04-01       Impact factor: 2.080

Review 9.  Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.

Authors:  Mary Glorieux; Rüveyda Dok; Sandra Nuyts
Journal:  Oncotarget       Date:  2017-09-16

10.  Radiolabeled F(ab')2-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models.

Authors:  P-S Bellaye; M Moreau; O Raguin; A Oudot; C Bernhard; J-M Vrigneaud; L Dumont; D Vandroux; F Denat; A Cochet; F Brunotte; B Collin
Journal:  Clin Transl Oncol       Date:  2018-05-17       Impact factor: 3.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.